Zacks Research Analysts Decrease Earnings Estimates for WST

West Pharmaceutical Services, Inc. (NYSE:WST) – Investment analysts at Zacks Research decreased their Q3 2025 earnings estimates for shares of West Pharmaceutical Services in a research note issued to investors on Wednesday, April 9th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will earn $1.64 per share for the quarter, down from their prior forecast of $1.65. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ FY2025 earnings at $6.18 EPS, Q1 2026 earnings at $1.40 EPS, Q2 2026 earnings at $1.78 EPS, Q3 2026 earnings at $1.91 EPS, Q4 2026 earnings at $2.00 EPS, FY2026 earnings at $7.09 EPS, Q1 2027 earnings at $1.56 EPS and FY2027 earnings at $8.17 EPS.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The business had revenue of $748.80 million for the quarter, compared to analyst estimates of $739.59 million.

Other research analysts have also issued reports about the company. Evercore ISI started coverage on West Pharmaceutical Services in a report on Tuesday, March 18th. They set an “outperform” rating and a $275.00 target price on the stock. Citigroup began coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a research note on Friday, February 14th. StockNews.com cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Thursday, February 27th. Finally, KeyCorp reduced their price objective on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, West Pharmaceutical Services currently has a consensus rating of “Moderate Buy” and an average price target of $332.50.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST opened at $210.75 on Friday. The stock has a market capitalization of $15.24 billion, a PE ratio of 31.50, a price-to-earnings-growth ratio of 6.74 and a beta of 1.22. West Pharmaceutical Services has a 52 week low of $187.43 and a 52 week high of $394.42. The stock has a 50 day moving average price of $231.81 and a 200 day moving average price of $289.85. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.23 and a current ratio of 2.79.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 7th. Stockholders of record on Wednesday, April 30th will be given a dividend of $0.21 per share. The ex-dividend date is Wednesday, April 30th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.40%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.56%.

Institutional Trading of West Pharmaceutical Services

Hedge funds have recently bought and sold shares of the business. Whipplewood Advisors LLC purchased a new position in West Pharmaceutical Services in the 4th quarter worth $25,000. Retirement Wealth Solutions LLC purchased a new position in West Pharmaceutical Services during the fourth quarter valued at $34,000. Centricity Wealth Management LLC bought a new stake in West Pharmaceutical Services during the fourth quarter valued at about $35,000. Cornerstone Planning Group LLC boosted its holdings in shares of West Pharmaceutical Services by 57.1% during the 4th quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 40 shares during the last quarter. Finally, Private Trust Co. NA raised its position in shares of West Pharmaceutical Services by 138.6% during the 4th quarter. Private Trust Co. NA now owns 136 shares of the medical instruments supplier’s stock valued at $45,000 after buying an additional 79 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.